Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab

Trial Profile

Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 20 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01579357).
    • 20 Apr 2012 Planned End Date changed from 28 Oct 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top